Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivastigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 17/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 11/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.86 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivastigmine SCHEMBL6382107 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL13841811 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL29614698 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL1170429 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL6382629 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL5803794 | 0.99 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL16568160 | 0.99 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL916695 | 0.99 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL15519471 | 0.95 | ACHE (0.90) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL25232361 | 0.93 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34405 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4429648-B1 | NOVEL SYNERGISTIC COMBINATIONS BASED ON FLUOROETHYLNOREMMANTINE (FENM) AND AN ACETYLCHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF NEURODEGEATIVE DISEASES | REST THERAPEUTICS (FR) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090265-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2508 BIOSCIENCES LLC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| WO-2000033840-A1 | USE OF ACETYLCHOLINESTERASE INHIBITORS ON THE MODULATION OF THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS | BONNIE DAVIS (US) | 2000-06-15 | — | — | WO | claimed |
| WO-2000030446-A1 | DOSAGE FORMULATIONS FOR ACETYLCHOLINESTERASE INHIBITORS | BONNIE DAVIS (US) | 2000-06-02 | — | — | WO | claimed |
| WO-2000025821-A1 | METHOD OF TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME AND CORRESPONDING MEANS | HEDNER JAN (SE) | 2000-05-11 | — | — | WO | claimed |
| WO-2000023057-A2 | ATYPICAL ANTIPHSYCHOTIC IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITOR FOR IMPROVING COGNITION | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-27 | — | — | WO | claimed |
| WO-2000019985-A2 | NEW SUSTAINED RELEASE ORAL FORMULATIONS | NOVARTIS AG (CH) | 2000-04-13 | — | — | WO | claimed |
| WO-2000015205-A2 | USE OF ACETYLCHOLINESTERASE INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FUNCTIONAL AND/OR ORGANIC PAIN SYNDROMES | EISAI CO., LTD. (JP) | 2000-03-23 | — | — | WO | claimed |
| EP-0952826-A1 | IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE | Takeda Chemical Industries, Ltd. (JP) | 1999-11-03 | — | — | EP | claimed |
| WO-1999025363-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 1999-05-27 | — | — | WO | claimed |
| WO-1998031356-A1 | IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-07-23 | — | — | WO | claimed |
| WO-1998030243-A1 | ACETYLCHOLINESTERASE INHIBITORS IN COMBINATION WITH MUSCARINIC AGONISTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | WARNER-LAMBERT COMPANY (US) | 1998-07-16 | — | — | WO | claimed |